High rates of resistance to cephalosporins among viridans-group streptococci causing bacteraemia in neutropenic cancer patients

被引：41

作者：

Marron, A

Carratalà, J

Alcaide, F

Fernández-Sevilla, A

Gudiol, F

机构：

[1] Univ Barcelona, Inst Catala Oncol, Bellvitge Hosp, Infect Dis Serv, Barcelona, Spain

[2] Univ Barcelona, Inst Catala Oncol, Bellvitge Hosp, Microbiol Serv, Barcelona, Spain

[3] Univ Barcelona, Inst Catala Oncol, Bellvitge Hosp, Serv Clin Haematol, Barcelona, Spain

来源：

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2001年 / 47卷 / 01期

关键词：

D O I：

10.1093/jac/47.1.87

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

The prevalence of resistance to cephalosporins among viridans-group streptococci causing 88 (18%) cases among 485 bacteraemias in neutropenic cancer patients was studied. Rates of resistance to ceftriaxone, ceftazidime, cefpirome and cefepime were 22, 53, 14 and 34%, respectively. Previous administration of(l-lactam therapy was the only factor significantly associated with bacteraemia due to cephalosporin-resistant strains; only 11 (16%) of 68 patients infected with cephalosporin-susceptible bacteria had received these antibiotics compared with 10(50%) of 20 patients infected with cephalosporin-resistant bacteria (P = 0.0052).

引用

收藏

页码：87 / 91

页数：5

相关论文

共 11 条

[1]

[Anonymous], 1993, M7A3 NCCLS

[2] Nomenclature for aerobic and facultative bacteria [J].

Bruckner, DA ;

Colonna, P .

CLINICAL INFECTIOUS DISEASES, 1997, 25 (01) :1-10

[3] BACTEREMIA DUE TO VIRIDANS STREPTOCOCCI THAT ARE HIGHLY RESISTANT TO PENICILLIN - INCREASE AMONG NEUTROPENIC PATIENTS WITH CANCER [J].

CARRATALA, J ;

ALCAIDE, F ;

FERNANDEZSEVILLA, A ;

CORBELLA, X ;

LINARES, J ;

GUDIOL, F .

CLINICAL INFECTIOUS DISEASES, 1995, 20 (05) :1169-1173

[4] Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States [J].

Doern, GV ;

Ferraro, MJ ;

Brueggemann, AB ;

Ruoff, KL .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (04) :891-894

[5] SEPTICEMIA AND SHOCK SYNDROME DUE TO VIRIDANS STREPTOCOCCI - A CASE-CONTROL STUDY OF PREDISPOSING FACTORS [J].

ELTING, LS ;

BODEY, GP ;

KEEFE, BH .

CLINICAL INFECTIOUS DISEASES, 1992, 14 (06) :1201-1207

[6] Outcomes of bacteremia in patients with cancer and neutropenia: Observations from two decades of epidemiological and clinical trials [J].

Elting, LS ;

Rubenstein, EB ;

Rolston, KVI ;

Bodey, GP .

CLINICAL INFECTIOUS DISEASES, 1997, 25 (02) :247-259

[7] Ceftriaxone monotherapy in the treatment of low-risk febrile neutropenia [J].

Karthaus, M ;

Wolf, HH ;

Kampfe, D ;

Egerer, G ;

Ritter, J ;

Peters, G ;

Sudhoff, T ;

Franke, A ;

Heil, G ;

Kullmann, KH ;

Jurgens, H .

CHEMOTHERAPY, 1998, 44 (05) :343-354

[8]

*NAT COMM CLIN LAB, 1997, M100S7M7A4 NCCLS

[9] In vitro activity of cefepime and ceftazidime against 197 nosocomial blood stream isolates of streptococci: A multicenter sample [J].

Pfaller, MA ;

Marshall, SA ;

Jones, RN .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1997, 29 (04) :273-276

[10] INVITRO ANTIMICROBIAL SUSCEPTIBILITY OF VIRIDANS STREPTOCOCCI ISOLATED FROM BLOOD CULTURES [J].

POTGIETER, E ;

CARMICHAEL, M ;

KOORNHOF, HJ ;

CHALKLEY, LJ .

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1992, 11 (06) :543-546